The antipsychotic Zypadhera, used to treat schizophrenia, is temporarily available on a limited basis. Shortages are likely to persist until February. The National Medicines Coordination Center advises practitioners to adjust the treatment. Patients are often given the drug in high doses by injection. The Medicines Evaluation Board (MEB) and NOS report this.
The shortage means that patients have to switch medicines, which is often undesirable, especially for vulnerable groups. This makes the risk that they will end up in psychosis even greater. The shortage can also cause people to stop taking medication, out of fear of other medications or because of stress. This also promotes psychoses.
Do not start a new treatment with Zypadhera
About 1,400 people in the Netherlands are prescribed Zypadhera. Patients who were going to start it are now being duped by this. The MEB advises practitioners not to start new treatments with Zypadhera. The treatment for existing patients will be adjusted to a single dose of 300 milligrams and practitioners are advised to opt for a shorter treatment interval. The treatment advice applies until February 2, 2024.
By: National Healthcare Guide / Johanne Levinsky
2024-01-19 12:45:03
#Severe #deficiency #antipsychotic #Zypadhera #greater #risk #psychoses